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Microorganisms of the genus Methylobacterium are facultative methylotrophic, gram-negative rods that are ubiquitous in nature
and rarely cause human disease, mostly in subjects with preexisting causes of immune depression. Methylobacterium fujisawaense,
first proposed as a new species in 1988, has never been reported as a bacterial agent of human infections so far. Here we
describe a case of M. fujisawaense infection in a relapsed acute leukaemia undergoing unrelated allogeneic hematopoietic stem cell
transplantation. Molecular identification of an M. fujisawaense strain was obtained from multiple mycobacterial blood cultures.
1. Introduction
The genus Methylobacterium, first proposed by Patt in 1976,
consists of more than 20 strictly aerobic species of pink-
pigmented, facultative methylotrophic, gram-negative rods
that are widely distributed in nature and have been occa-
sionally isolated from aqueous environments (as discussed
by Furuhata et al. [1]). They rarely cause human disease,
mostly in immunocompromised patients with solid or
hematologic neoplasms, AIDS, renal failure, tuberculosis, or
alcoholism (as discussed by Truant et al. [2]). Within such
genus, Methylobacterium mesophilicum is the species more
frequently reported as responsible for infections in humans
(as discussed by Sanders et al. [3]). Methylobacterium
fujisawaense, first described by Green in 1988 (as discussed
by Green et al. [4]), has never been isolated from humans so
far; here we report its isolation from the blood of an adult
patient undergoing unrelated allogeneic hematopoietic stem
cell transplantation (HSCT) after relapsing acute myeloid
leukemia (AML).
2. Case Presentation
A 57-year-old Caucasian female was admitted to the haema-
tology unit in May 2006 for AML, M2 FAB subtype, CD 34+,
normal karyotype, and FLT3+ by internal tandem dupli-
cations. After standard induction chemotherapy and con-
solidation, the patient underwent a peripheral autologous
HSCT while in complete remission because of unavailability
of a matched-related donor. In April 2007, AML relapsed
and a course of reinduction therapy was started. In June
2007, the patient underwent a new peripheral HSCT from
an unrelated donor, without any serious infectious compli-
cation in the aplastic period. Antibacterial and antifungal
prophylaxis consisted of oral ciprofloxacin (500mgx2/day)
and oral itraconazole (400mg/day) was started on day −7.
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CMV prophylaxis was with ganciclovir 10mg/kg from day
−7 to −2 and foscarnet 90mg/kg from day +4 to +20.
GVHD prophylaxis consisted of cyclosporine/methotrexate
and antithymocyte globulin (ATG).
Complete engraftment was on day +21. On day +30,
while blood examination revealed a neutrophil count
>500/mmc and a lymphocyte count of 1.7 × 109/L, afebrile
episode (39◦C) with chills and malaise occurred. Blood
cultures were obtained from both peripheral vein and central
venous catheter (CVC, Groshong) by Bactec Plus Aerobic/F
and Bactec Plus Anaerobic/F bottles. After incubation for
five days and reading by the instrumentation Bactec 9240
(Becton, Dickinson and Co. Sparks, USA), blood cultures
were positive for a Pseudomonas aeruginosa strain that was
susceptible to amikacin, imipenem, meropenem, cefepime,
ceftazidime, piperacillin, and piperacillin/tazobactam, so
intravenous piperacillin/tazobactam 4.5 g tid was initiated.
Chest X-ray and pulmonary CT scan performed after seven
days of persistent fever showed a cavitary lesion interpreted
as a possible mycotic infection. Though Aspergillus galac-
tomannan antigenemia test and cultures from both sputum
and bronchoalveolar lavage (BAL) were negative, antifungal
therapy with intravenous voriconazole 200mg bid and then
with liposomal amphotericin B 3mg/kg/day was added. After
a clinical improvement, the patient was discharged with oral
voriconazole treatment. In the first week of September 2007,
on the occasion of a new febrile episode, a second CT scan
did not reveal lung improvement. After her admission to
the Infectious Diseases unit in September, six blood cultures
(three from peripheral vein and three from CVC), sputum,
BAL samples and Aspergillus galactomannan antigenemia
were collected for microbiological investigations. It was not
possible to obtain cultures through pulmonary biopsy.
Respiratory samples grew a strain of P. aeruginosa with
a resistance phenotype identical to that of the previously
isolated strain. A strain with a similar resistance profile was
also isolated from a large necrotic mouth ulcer occurring at
that time; antibiotic therapy with intravenous meropenem
1 g tid was promptly started, with transitory improvement.
On September 13, local signs of insertion infection appeared,
so CVC was removed and its tip was cultured, but no
bacterial or fungal growth was observed. The patient con-
tinued to suffer from infrequent episodes of low-grade fever
(37.5◦C) for 10 days. Among the six blood samples taken in
September, the ones investigated for aerobic and anaerobic
bacteria remained negative. On the other part, five out
of six ones aiming to 5 mycobacteria obtained by Bactec
13A bottles, incubated for eight weeks, and read by the
instrumentation Bactec 460TB (Becton, Dickinson and Co.
Sparks, USA), yielded a non-acid-fast bacillus. Such blood
cultures were reported as contaminated but, because of its
unique features, the organism was further investigated and
two weeks later identified as M. fujisawaense by means of
genetic sequencing of 16S rDNA. The genetic sequencing
was carried out with universal primers (5′-GTATTACCG-
CGGCTGCTG-3′ and 5-AAGAGTTTGATCATGGCTCAF-
3′) using BigDye Terminator chemistry and an AB 3730 DNA
sequencer (Applied Biosystems).
3. Susceptibility
Testing performed on Muller Hinton using E-test
method revealed susceptibility only to imipenem (MIC,
0.125mcg/ml), so confirming the data of the medical
literature(as discussed by Zaharatos et al. [5]). A new
sputum sample collected after ten days of treatment grew
a P. aeruginosa strain resistant to carbapenems but still
susceptible to the other drugs tested. The intravenous
therapy was then changed to cefepime 2 g bid plus amikacin
1 g once daily. On September 30, the patient, still afebrile,
was discharged with the prescription of continuing the
latter antimicrobial therapy for a total of four weeks. At
the end of October 2007, the patient was readmitted to the
haematology unit with high fever and a relapse of AML, in
absence of graft-versus-host disease (GVHD) symptoms.
After temporary reduction of fever, a persistent, high (40◦C)
temperature spike developed, and the patient died four days
apart with a clinical picture of septic shock although in
absence of any bacterial isolation from new blood samples.
No autopsy was performed.
4. Discussion
Members of the genus Methylobacterium are ubiquitous
in nature and can be detected in soil and freshwater
environments including drinking water (as discussed by
Gallego et al. [6]). M. fujisawaense was proposed as a new
species in 1988 (as discussed by Green et al. [4]); so far
neither it has been reported as a human pathogen nor it
has been isolated from clinical specimens. In contrast, M.
mesophilicum has been isolated from blood, bone marrow,
skin, sputum, pleural effusion, and dyalisate of patients with
clinically suspected infection (as discussed by Sanders et al.
[3]). Scanty information concerning M. fujisawaense reports
its isolation from tap water and its susceptibility to imipenem
and tetracycline only, (as discussed by Furuhata et al. [1])
whereas most Methylobacterium species are sensitive even to
aminoglycosides, ceftizoxime, ceftriaxone, ciprofloxacin, and
cotrimoxazole (as discussed by Brown et al. [7]). Discordant
carbapenem susceptibility, with sensitivity to imipenem and
resistance to meropenem, seems to be a distinctive feature
of Methylobacterium species (as discussed by Zaharatos et
al. [5]). We report here, for the first time, the isolation of a
M. fujisawaense strain from blood cultures during a febrile
episode in an immunocompromised patient undergoing
HSCT after relapsing AML. As our patient was previously
infected by a multiresistant P. aeruginosa strain likely causing
pulmonary infiltrates with necrotizing lesions, the role of
this microorganism remains unclear. The fastidious growth
of M. fujisawaense may well explain the lack of previous
clinical reports. In this case, it was fortuitously detected
in multiple mycobacterial blood cultures. Indeed, M. fuji-
sawaense was able to grow in the radiometric broth specific
for mycobacteria, and its detection was made possible by
the longer incubation of mycobacterial blood cultures in
comparison with the routine ones. Clinical interpretation
of microbiological tests can be sometimes problematic, and
conclusions should be drawn with prudence. However, the
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fact that M. fujisawaense was isolated from multiple blood
samples, collected from both peripheral vein and CVC,
suggests the presence of a systemic infection caused by this
organism and excludes the hypothesis of contamination or
colonization in our ward; moreover, laboratory contami-
nation was very improbable, as blood transfer from the
collection tube to the culture bottle by a sterile syringe and
under laminar flow cabinet was the only operation carried
out in the laboratory. After catheter removal, M. fujisawaense
was no longer found in blood cultures, even if the patient
was never treated with imipenem. Actually as CVC is the
most common portal of Methylobacterium infection, most
experts recommend catheter removal, as part of treatment
along with appropriate antibiotic regimens (as discussed by
Sanders et al. [3] and Fernandez et al. [8]). Although rare,
infections with Methylobacterium species are now reported—
particularly in immunocompromised patients—because of
the improvement of identification methods. Isolation of
those unusual pathogens should not be disregarded by
microbiologists, their potentially infectious role should not
be denied by clinicians, and all possible sources should be
investigated. The availability of molecular tools is crucial to
correctly identify rare microorganisms and contribute to the
emergence of previously unrecognized diseases.
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